You Searched For: Competent+Cells


134,043  results were found

SearchResultCount:"134043"

Sort Results

List View Easy View

Rate These Search Results

Catalog Number: (10105-318)
Supplier: Prosci
Description: MXD4 is a member of the MAD gene family. The MAD genes encode basic helix-loop-helix-leucine zipper proteins that heterodimerize with MAX protein, forming a transcriptional repression complex. The MAD proteins compete for MAX binding with MYC, which heterodimerizes with MAX forming a transcriptional activation complex. Studies in rodents suggest that the MAD genes are tumor suppressors and contribute to the regulation of cell growth in differentiating tissues.


Catalog Number: (10764-798)
Supplier: Prosci
Description: The RPA-T8 monoclonal antibody specifically reacts with the human CD8a molecule, a 32 kDa cell surface receptor expressed either as a heterodimer (CD8 alpha/beta) or as a homodimer (CD8 alpha/alpha) on the majority of thymocytes, a subpopulation of mature T cells, and natural killer cells. CD8 interacts with the major histocompatibility complex class I (MHC class I) molecules on antigen-presenting cells or epithelial cells. The RPA-T8 antibody reacts with 13-48% of peripheral lymphocytes, 80% of thymocytes, and a subset of natural killer cells. RPA-T8, OKT8, and HIT8a antibodies do not compete with each other for binding to peripheral leukocytes, meaning that that they do not recognize the same epitope or block each other by steric hindrance.


Catalog Number: (10764-800)
Supplier: Prosci
Description: The RPA-T8 monoclonal antibody specifically reacts with the human CD8a molecule, a 32 kDa cell surface receptor expressed either as a heterodimer (CD8 alpha/beta) or as a homodimer (CD8 alpha/alpha) on the majority of thymocytes, a subpopulation of mature T cells, and natural killer cells. CD8 interacts with the major histocompatibility complex class I (MHC class I) molecules on antigen-presenting cells or epithelial cells. The RPA-T8 antibody reacts with 13-48% of peripheral lymphocytes, 80% of thymocytes, and a subset of natural killer cells. RPA-T8, OKT8, and HIT8a antibodies do not compete with each other for binding to peripheral leukocytes, meaning that that they do not recognize the same epitope or block each other by steric hindrance.


Catalog Number: (75842-032)
Supplier: BIOGEMS INTERNATIONAL INC.
Description: The Hit8a monoclonal antibody reacts with the human CD8a molecule, a 32 kDa cell surface receptor expressed either as a heterodimer (CD8 α/β) or as a homodimer (CD8 α/α) on the majority of thymocytes, a subpopulation of mature T cells, and natural killer cells. CD8 interacts with the major histocompatibility complex class I (MHC class I) molecules on antigen-presenting cells or epithelial cells. The Hit8a antibody reacts with 13-48% of peripheral lymphocytes, 80% of thymocytes, and a subset of natural killer cells. HIT8a, RPA-T8, and OKT8 antibodies do not compete with each other for binding to peripheral leukocytes, meaning that that they do not recognize the same epitope or block each other by steric hindrance.


Catalog Number: (75844-258)
Supplier: BIOGEMS INTERNATIONAL INC.
Description: The RPA-T8 monoclonal antibody specifically reacts with the human CD8a molecule, a 32 kDa cell surface receptor expressed either as a heterodimer (CD8 α/β) or as a homodimer (CD8 α/α) on the majority of thymocytes, a subpopulation of mature T cells, and natural killer cells. CD8 interacts with the major histocompatibility complex class I (MHC class I) molecules on antigen-presenting cells or epithelial cells. The RPA-T8 antibody reacts with 13-48% of peripheral lymphocytes, 80% of thymocytes, and a subset of natural killer cells. RPA-T8, OKT8, and HIT8a antibodies do not compete with each other for binding to peripheral leukocytes, meaning that that they do not recognize the same epitope or block each other by steric hindrance.


Catalog Number: (75843-074)
Supplier: BIOGEMS INTERNATIONAL INC.
Description: The RPA-T8 monoclonal antibody specifically reacts with the human CD8a molecule, a 32 kDa cell surface receptor expressed either as a heterodimer (CD8 α/β) or as a homodimer (CD8 α/α) on the majority of thymocytes, a subpopulation of mature T cells, and natural killer cells. CD8 interacts with the major histocompatibility complex class I (MHC class I) molecules on antigen-presenting cells or epithelial cells. The RPA-T8 antibody reacts with 13-48% of peripheral lymphocytes, 80% of thymocytes, and a subset of natural killer cells. RPA-T8, OKT8, and HIT8a antibodies do not compete with each other for binding to peripheral leukocytes, meaning that that they do not recognize the same epitope or block each other by steric hindrance.


Catalog Number: (10100-466)
Supplier: Prosci
Description: IL15 is a cytokine that regulates T and natural killer cell activation and proliferation. This cytokine and interleukine 2 share many biological activities. They are found to bind common hematopoietin receptor subunits, and may compete for the same receptor, and thus negatively regulate each other's activity. The number of CD8+ memory cells is shown to be controlled by a balance between this cytokine and IL2. This cytokine induces the activation of JAK kinases, as well as the phosphorylation and activation of transcription activators STAT3, STAT5, and STAT6. Studies of the mouse counterpart suggested that this cytokine may increase the expression of apoptosis inhibitor BCL2L1/BCL-x (L), possibly through the transcription activation activity of STAT6, and thus prevent apoptosis.The protein encoded by this gene is a cytokine that regulates T and natural killer cell activation and proliferation. This cytokine and interleukine 2 share many biological activities. They are found to bind common hematopoietin receptor subunits, and may compete for the same receptor, and thus negatively regulate each other's activity. The number of CD8+ memory cells is shown to be controlled by a balance between this cytokine and IL2. This cytokine induces the activation of JAK kinases, as well as the phosphorylation and activation of transcription activators STAT3, STAT5, and STAT6. Studies of the mouse counterpart suggested that this cytokine may increase the expression of apoptosis inhibitor BCL2L1/BCL-x (L), possibly through the transcription activation activity of STAT6, and thus prevent apoptosis. Two alternatively spliced transcript variants of this gene encoding the same protein have been reported.


Catalog Number: (10340-052)
Supplier: Bioss
Description: TNFRSF14 is a type I membrane protein belonging to the TNF receptor superfamily. This receptor mediates herpes virus entry into cells during infection. TNFRSF14 is able to inhibit the proliferation, activation, and cytokine production of T cells. It has an extracellular domain containing several cysteine-rich repeats and a short cytoplasmic region containing a TRAF (TNF receptor-associated factor) interaction domain. The extracellular domain of TNFRSF14 interacts with the herpes simplex virus envelope glycoprotein D. TNFRSF14 binds two cellular ligands: lymphotoxin alpha and LIGHT. LIGHT is a transmembrane protein expressed and shed from the surface of activated T cells, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes. The LIGHT:TNFRSF14 interaction controls immune response functions by cell death induction as well as cell activation. TNFRSF14 is expressed by peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells.


Catalog Number: (75844-252)
Supplier: BIOGEMS INTERNATIONAL INC.
Description: The RPA-T8 monoclonal antibody specifically reacts with the human CD8a molecule, a 32 kDa cell surface receptor expressed either as a heterodimer (CD8 α/β) or as a homodimer (CD8 α/α) on the majority of thymocytes, a subpopulation of mature T cells, and natural killer cells. CD8 interacts with the major histocompatibility complex class I (MHC class I) molecules on antigen-presenting cells or epithelial cells. The RPA-T8 antibody reacts with 13-48% of peripheral lymphocytes, 80% of thymocytes, and a subset of natural killer cells. RPA-T8, OKT8, and HIT8a antibodies do not compete with each other for binding to peripheral leukocytes, meaning that that they do not recognize the same epitope or block each other by steric hindrance.


Catalog Number: (75792-896)
Supplier: Prosci
Description: TRAIL-R3 is a receptor for the cytotoxic ligand TRAIL. It lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. Protects cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.


Catalog Number: (75843-076)
Supplier: BIOGEMS INTERNATIONAL INC.
Description: The RPA-T8 monoclonal antibody specifically reacts with the human CD8a molecule, a 32 kDa cell surface receptor expressed either as a heterodimer (CD8 α/β) or as a homodimer (CD8 α/α) on the majority of thymocytes, a subpopulation of mature T cells, and natural killer cells. CD8 interacts with the major histocompatibility complex class I (MHC class I) molecules on antigen-presenting cells or epithelial cells. The RPA-T8 antibody reacts with 13-48% of peripheral lymphocytes, 80% of thymocytes, and a subset of natural killer cells. RPA-T8, OKT8, and HIT8a antibodies do not compete with each other for binding to peripheral leukocytes, meaning that that they do not recognize the same epitope or block each other by steric hindrance.


Catalog Number: (75843-066)
Supplier: BIOGEMS INTERNATIONAL INC.
Description: The RPA-T8 monoclonal antibody specifically reacts with the human CD8a molecule, a 32 kDa cell surface receptor expressed either as a heterodimer (CD8 α/β) or as a homodimer (CD8 α/α) on the majority of thymocytes, a subpopulation of mature T cells, and natural killer cells. CD8 interacts with the major histocompatibility complex class I (MHC class I) molecules on antigen-presenting cells or epithelial cells. The RPA-T8 antibody reacts with 13-48% of peripheral lymphocytes, 80% of thymocytes, and a subset of natural killer cells. RPA-T8, OKT8, and HIT8a antibodies do not compete with each other for binding to peripheral leukocytes, meaning that that they do not recognize the same epitope or block each other by steric hindrance.


Supplier: Adipogen
Description: Potent, cell permeable and specific protein arginine N-methyltransferase 1 (PRMT1) inhibitor (IC50 = 8.8 µM). Does not compete for the AdoMet (S-adenosyl-L-methionine; SAM) binding site. Blocks peptide substrate binding. HIV-1 RT polymerase inhibitor (IC50 = 5.0 µM).

Small Business Enterprise

Catalog Number: (102515-628)
Supplier: Adipogen
Description: TRAIL-R1, -R2, -R3 and -R4 are receptors for the cytotoxic ligand TRAIL. When signaling through TRAIL-R1 and -R2, the adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. They promote the activation of NF-kappaB. TRAIL-R3 lacks a cytoplasmic death domain, and TRAIL-R4 contains a truncated death domain, and hence are not capable of inducing apoptosis. They protect cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.

Small Business Enterprise


Catalog Number: (75843-070)
Supplier: BIOGEMS INTERNATIONAL INC.
Description: The RPA-T8 monoclonal antibody specifically reacts with the human CD8a molecule, a 32 kDa cell surface receptor expressed either as a heterodimer (CD8 α/β) or as a homodimer (CD8 α/α) on the majority of thymocytes, a subpopulation of mature T cells, and natural killer cells. CD8 interacts with the major histocompatibility complex class I (MHC class I) molecules on antigen-presenting cells or epithelial cells. The RPA-T8 antibody reacts with 13-48% of peripheral lymphocytes, 80% of thymocytes, and a subset of natural killer cells. RPA-T8, OKT8, and HIT8a antibodies do not compete with each other for binding to peripheral leukocytes, meaning that that they do not recognize the same epitope or block each other by steric hindrance.


Catalog Number: (75843-058)
Supplier: BIOGEMS INTERNATIONAL INC.
Description: The RPA-T8 monoclonal antibody specifically reacts with the human CD8a molecule, a 32 kDa cell surface receptor expressed either as a heterodimer (CD8 α/β) or as a homodimer (CD8 α/α) on the majority of thymocytes, a subpopulation of mature T cells, and natural killer cells. CD8 interacts with the major histocompatibility complex class I (MHC class I) molecules on antigen-presenting cells or epithelial cells. The RPA-T8 antibody reacts with 13-48% of peripheral lymphocytes, 80% of thymocytes, and a subset of natural killer cells. RPA-T8, OKT8, and HIT8a antibodies do not compete with each other for binding to peripheral leukocytes, meaning that that they do not recognize the same epitope or block each other by steric hindrance.


Inquire for Price
Stock for this item is limited, but may be available in a warehouse close to you. Please make sure that you are logged in to the site so that available stock can be displayed. If the call is still displayed and you need assistance, please call us at 1-800-932-5000.
Stock for this item is limited, but may be available in a warehouse close to you. Please make sure that you are logged in to the site so that available stock can be displayed. If the call is still displayed and you need assistance, please call us at 1-800-932-5000.
This product is marked as restricted and can only be purchased by approved Shipping Accounts. If you need further assistance, email VWR Regulatory Department at Regulatory_Affairs@vwr.com
-Additional Documentation May be needed to purchase this item. A VWR representative will contact you if needed.
This product has been blocked by your organization. Please contact your purchasing department for more information.
The original product is no longer available. The replacement shown is available.
This product is no longer available. Alternatives may be available by searching with the VWR Catalog Number listed above. If you need further assistance, please call VWR Customer Service at 1-800-932-5000.
257 - 272 of 134,043
no targeter for Bottom